This study investigates the effects of an investigational medication on acne in male participants. Acne is a skin condition that occurs when hair follicles become clogged with oil and dead skin cells, leading to pimples, blackheads, or nodules. The study will involve male subjects aged 18 to 35 who have at least ten nodular lesions, which are painful lumps under the skin. Participants will be randomly assigned to one of three study arms: a group receiving 23.5 mg of the investigational medication, a group receiving 33.5 mg, or a placebo group, which is an inactive substance that looks like the investigational medication but does not contain any medicine.

Participants will undergo various procedures during the study. Initially, there will be a screening period to review eligibility, conduct laboratory tests, and perform medication washouts if needed. Subsequently, a baseline assessment will be conducted, including acne lesion counts and physical examinations. Throughout the 12-week treatment period, participants will visit the study site multiple times for acne assessments, diary reviews, and monitoring of any side effects. At the end of the study, a final assessment will be conducted to evaluate the treatment's efficacy and gather feedback from participants.

• Who can participate: The study is open to males aged 18 to 35 years who have at least ten nodular lesions and are in generally good health. Participants must weigh between 40 and 110 kg and be able to swallow pills. They should also agree to use a barrier-method contraception.
• Study details: Participants will be required to complete questionnaires on sexual function and depression, and undergo physical examinations and acne lesion counts. They will also need to visit the study site at specified intervals for assessments and to review their diaries.
• Study Timelines and Visits: The study will last 12 weeks. The study requires 4 visits.